Pharmacovigilance program in Indonesia has been started and promoted by NADFC (National Agency for Drug and Food Control) as the national drug control authority. The main goal of pharmacovigilance program is not only to improve patient's safety of using drugs, but also to contribute towards the evaluation of benefit, danger, effectiveness and risks of using certain drugs, and also to encourage the safety, rationality, and effectiveness (including cost savings) of using drugs.
So far, the system that has been adopted in Indonesia concerning this activity is a spontaneous report delivered by health professionals using a yellow form which is a standard report of adverse drug reactions. It needs efforts to improve feedbacks because the reporting rate of spontaneous reporting system is still low compared to the number of population or the number of drugs distributed in Indonesia. To overcome these challenges, Indonesia has to strengthen they system and network of pharmacovigilance in all areas and healthcare facilities.
Based on what have been done, WHO once again offered its supports to NADFC to strengthen the program of pharmacovigilance in Indonesia by holding a workshop for health professionals with the theme of Strengthening Drug Safety Monitoring in Indonesia—National Pharmacovigilance Workshop from October 23 to October 25, 2017 in Bekasi. The workshop was attended by 135 participants consisting of hospitals and Community Health Centers in Sumatra, Java, and Bali, Health Department of DKI Jakarta (either Provincial Health Department or Public Health Service of DKI Jakarta), Health Department of Bekasi City, Health Department of Tanggerang City, and also Provincial Office of NADFC in Jakarta, Bandung, Semarang, Surabaya and Serang.
Besides presenters of NADFC, other presenters participating in the workshop were Dr. Jarir at Thobari, PhD (UGM); Dra. Yulia Trisna, Apt, M.Phrm (KARS); Prof Dr. Sri Suryawati, Apt (IAI); M. Ch. Reza Kartika P.R. S.Farm. Apt (RSK St. Vincentius a Pulo) and Dr. Widyati, MClin Pharm, Apt (RSAL Dr. Ramelan).
It is expected that the workshop can increase awareness and develop the capacity of pharmacovigilance for health professionals. It is also expected to intensify the network among stakeholders and to improve important knowledge of theory, practice and skills for developing the activities of pharmacovigilance in health services at health service facilities.